Join the club for FREE to access the whole archive and other member benefits.

Tune Therapeutics

Epi-therapeutic medicines working on epigenome editors

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows  to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Their approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.

Visit website: https://tunetx.com/

 tunetx

 tunetx_news

Details last updated 01-Jul-2022

Mentioned in this Resource

Fyodor Urnov

Scientific director for technology and translation, IGI, UC Berkeley

Other people at Tune Therapeutics

Akira Matsuno

Co-Founder, President & CFO at Tune Therapeutics

Tune Therapeutics News

Epigenome editing - technology  safer and reversible than CRISPR

Epigenome editing - technology safer and reversible than CRISPR

Science - 01-Jun-2022

Leaves DNA sequence unaltered while retaining the ability to specifically home